By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Last week I wrote about why every entrepreneur needs to build a fundraising campaign that utilizes comprehensive marketing collateral and includes a strategy for getting in front of the right partners to help move your company forward. However, equally as important is an innovative technology, a compelling story and sufficient data to prove how effective your product is.

Early stage innovators need to get their products developed through prototyping for a target market, then get out of the building and go after that market (investors, end users, channel partners) with their product info and validating data. The key is emphasizing and differentiating their technology, proving why they are different and telling the story of what that difference will mean.  You have to start telling the story early.  Preclinical and IND stages are where you want to be talking about how your technology will impact the existing landscape, and you must deliver a prototype with data to prove it.

The lean company model, in which LSN believes, is to get your technology going and take it to the potential partners in your space (LSN can identify them) that would be interested, and build momentum and relationship value through early stage interaction. Attending RESI, which is held every few months, allows you to regularly meet your potential partners face to face and develop deeper relationships as the products iterate, instead of meeting once or twice a year. This is why RESI is so pivotal: because all the different but relevant players are at every RESI. LSN provides the tactical aspect of how to engage partners in discussion and where to find them.

Ultimately, a company cannot succeed without using all of these pieces to put together a complete picture: a product that continues to meet important milestones, a compelling story backed up by a complete marketing collateral package, and on-going relationships with investors and strategic partners to move it forward. However, the product and the validation data is the foundation on which everything stands, and it needs to be solid to avoid crashing to the ground.

By Claire Jeong, Director of Research, Asia BD, LSN

After finishing off our most successful RESI to date and recovering from JPM week, we are ramping up our preparations for the upcoming RESI Europe Conference, which will be at the Hyatt Regency Paris Étoile on Monday, March 23^rd, 2020. We expanded into Europe for the first time last year, and it is super exciting to be able to go to Paris for our second European conference. We look forward to fostering valuable connections and relationships, as well as working with a lot of new companies and investors/strategic partners based in Europe.

We are anticipating over 200 investors to join us at the event from across the globe. Please take advantage of our Super Early Bird Rate by using our €100 discount code SUPEREBEU on our registration here (expires on Sunday, February 2^nd). Hope to see you in Paris!

CONFIRMED RESI EUROPE INVESTORS AND STRATEGIC PARTNERS

As of  January 30th, 2020

And More…

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

All global incubators and accelerators will soon be up against an emerging global trend, where there are exponentially more fundable technology assets then investors and channel partners. I have been watching this develop over the 7 years I have been running RESI and in deep dialogue with the global investor market. I truly believe that ONLY the best prepared and packaged companies who are plugged into a global funding network will get the cash and partnerships needed to reach the market.

The LSN message, based on RESI, our dialogue with investors and strategic partners, and our training program, is to get early stage innovators in front of as many potential partners as possible (that are a fit) and that this interaction will create compelling relationships that can lead to capital allocations and licensing deals. LSN training programs are a bit different than then other entrepreneurial programs; essentially, the LSN theme is to take the scientist-entrepreneurs and teach them a small but gigantically important portion of basic sales, marketing and business development 101. We know they will not turn into sales experts, but we can get them some basic sales, marketing, and business development knowledge. Below are some of the main differentiators that LSN offers:

• How to get a list of partners that are a fit for your stage of development and product set. LSN Investor Platform has 5K global profiles
• How to define your competitive landscape. LSN Business Development Platform has 55K profiles
• How to set up a CRM to “manage and curate that list” of potential partners that are a fit and you need to reach as part of an ongoing campaign
• How to create and execute an email and phone canvassing. Yes, we teach how to write an intro email and how to pick up phone and make a call in our training labs
• How to do follow up calls, and then teach how to make the 2 to 20 follow up calls that need to be made
• How to use the RESI partnering system effectively to get as many meetings as possible

I think LSN has a bit of a different view and philosophy. All the branding and messaging LSN teaches is just to get partner meetings. That is it: essentially, how to organize your company’s branding and messaging to get in front of the right players and have that first meeting. I think the still commonly used broader, more sophisticated approach of figuring out the valuation and market size as part of their coaching is not where you want to spend a majority of your time. Predicting future sales and market size when you are preclinical, nascent startup is blindfolded forecasting. Rather, we teach PhDs to concentrate on getting the technology turned into a prototype with compelling proof of concept (data) that can be shown to the market players. Enter LSN, that connects the scientist-entrepreneur to the market player. The market players, if interested, will help determine value as the data and product takes shape and the relationship develops. LSN believes that if the fit is there, both parties will work together to achieve maximum success for the product and the market.

By Chris Kennedy, Vice President Strategic Initiatives, 4D Meets AI, LSN

LSN is taking a strategic step forward in 2020 and introducing 4D Meets AI, a new one day conference event that will stand beside RESI Boston in September.

Artificial Intelligence (AI) is a transformative force in the healthcare industry. From hospital care to clinical research, drug development and pathology,  AI applications are revolutionizing how the health sector works to reduce spending and improve patient outcomes.

The 4D Meets AI conference is organized around those early stage companies in the Drug, Device, Diagnostic and Digital Health verticals, the “4Ds”, companies that are pursuing the integration of technology, using new tools and applying methodologies that AI brings to this dynamic sector. AI will fundamentally reshape the healthcare landscape as we know it today.

LSN created the 4D Meets AI conference stemming from the success of our long-standing RESI conference series. It will continue doing what LSN does best, connecting early stage companies that develop cutting-edge AI technology in drugs, devices, diagnostics and digital health with the right investors, decision makers and thought leaders in this dynamic developing landscape.

We will launch registration soon, so stay tuned!  4D Meets AI is a unique opportunity to connect with early stage companies and investors in the healthcare AI space; if you are interested in sponsoring the event to boost your visibility, please reach out to me at c.kennedy@lifesciencenation.com.

A private investment firm based in New York invests in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm based in London, UK that focuses exclusively on healthcare seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

The firm is technology and indication agnostic, but intends to focus on innovative medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience. The firm will consider companies with products in the clinic as long as the company has at least one product that is on the market. The firm prefers to invest in companies who are headquartered or have a large presence in Europe. U.S.-based companies with a European angle will also be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech early stage investment fund founded in 2016 and headquartered in Taipei, Taiwan invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.